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Advances in DNA sequencing have made large, diagnostic gene panels affordable 
and efficient. Broad adoption of such panels has begun to deliver on the promises of 
personalized medicine, but has also brought new challenges such as the presence of 
unexpected results, or results of uncertain clinical significance. Genetic analysis of inher-
ited cardiac conditions is particularly challenging due to the extensive genetic hetero-
geneity underlying cardiac phenotypes, and the overlapping, variable, and incompletely 
penetrant nature of their clinical presentations. The design of effective diagnostic tests 
and the effective use of the results depend on a clear understanding of the relationship 
between each gene and each considered condition. To address these issues, we devel-
oped simple, systematic approaches to three fundamental challenges: (1) evaluating the 
strength of the evidence suggesting that a particular condition is caused by pathogenic 
variants in a particular gene, (2) evaluating whether unusual genotype/phenotype obser-
vations represent a plausible expansion of clinical phenotype associated with a gene, 
and (3) establishing a molecular diagnostic strategy to capture overlapping clinical pre-
sentations. These approaches focus on the systematic evaluation of the pathogenicity 
of variants identified in clinically affected individuals, and the natural history of disease 
in those individuals. Here, we applied these approaches to the evaluation of more than 
100 genes reported to be associated with inherited cardiomyopathies and arrhythmias 
including hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right 
ventricular dysplasia or cardiomyopathy, long QT syndrome, short QT syndrome,
Brugada, and catecholaminergic polymorphic ventricular tachycardia, and to a set of 
related syndromes such as Noonan Syndrome and Fabry disease. These approaches 
provide a framework for delivering meaningful and accurate genetic test results to indi-
viduals with hereditary cardiac conditions.
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inTrODUcTiOn
The dramatic reduction in the cost of DNA sequencing, combined 
with advances in the understanding of the genetic and phenotypic 
heterogeneity of cardiac conditions, has led to the adoption of 
large panels of genes as a cost-effective clinical tool to establish 
a molecular diagnosis in affected individuals. But, although the 
economics and the potential yield of such tests have improved, 
the fundamental principles of diagnostic testing – analytic valid-
ity, clinical validity, and clinical utility – have not.
Genetic diagnosis of inherited cardiac conditions is especially 
challenging due to the extensive genetic heterogeneity and the 
overlapping, variable, and incompletely penetrant nature of the 
clinical presentations. The design of effective diagnostic tests 
and the effective use of the results of such tests depend on a clear 
understanding of the relationship between each gene and each 
considered condition, and a clear understanding of the extent of 
the overlap in clinical presentation.
As part of an effort to develop a scalable framework for devel-
oping, launching, and supporting diagnostic genetic tests across a 
broad range of clinical areas, we set out to create general methods 
for establishing the clinical validity of a gene, and for designing 
focused and clinically useful panel tests.
Establishing the clinical validity of a multi-gene panel depends 
on an accurate and detailed understanding of the clinical valid-
ity of each included gene. While clinical laboratories have been 
implicitly making assessments regarding clinical validity for years, 
there has been a lack of clarity about evidentiary requirements for 
establishing clinical validity and, especially for rare, multigenic 
conditions, accessible data and methods to be applied in reaching 
this conclusion.
Within clinical genetic diagnostics, clinical validity “measures 
the accuracy with which a test identifies a person with the clinical 
condition in question” (1–3) and depends on such quantitative 
measures as sensitivity, specificity, positive predictive value and 
negative predictive value. While there are disagreements about 
quantitative thresholds for these measures, this is clear: a test that 
cannot return a positive result has no sensitivity and no posi-
tive predictive value, and cannot be considered clinically valid. 
Conceptually, clinical validity can be understood as a proven, 
causal connection between a gene and a human disease.
For diagnostic testing, the question of clinical validity should 
be thought of as only the first requirement. Once answered posi-
tively, it opens onto a series of more detailed considerations that 
also need evaluation. If it has been proven that the gene causes 
human disease (i.e., if clinical validity has been established) then 
one can reasonably ask: which disease(s)? How certain are we that 
we understand the boundaries of the phenotypic heterogeneity 
that can derive from this gene? What is the yield in different 
populations? Which specific variants are causal? How certain are 
we that we completely understand the molecular mechanisms? 
If, however, it has not yet been proven that a gene causes disease, 
then questions of expressivity and mechanism of disease are 
clouded by this more fundamental uncertainty.
This paper aims to (1) propose a method for establishing clini-
cal validity of a gene, (2) propose a method for grouping genes 
together into meaningful panel tests, and (3) apply those methods 
to evaluate a set of cardiac genes and conditions. We also describe 
the kinds of specific results that may be expected from clinical 
testing of different classes of genes, and the appropriate use of 
those results in clinical care.
MaTerials anD MeThODs
When we first began curating gene–condition relationships, we 
established a working group to develop a framework for evalu-
ating and documenting relevant evidence and our conclusions 
about that evidence. The working group consisted of lab directors, 
genetic counselors, and scientists with experience from a diversity 
of diagnostic and research labs. We first discussed and compared 
methods used in those environments, and quickly came to the 
conclusion that, while different approaches generally considered 
the same types of evidence (linkage studies, animal, cellular, and 
molecular models, observations of variants in affected individuals 
and pedigrees), there was little consensus about how to rigorously 
and reproducibly synthesize that evidence. In fact, in many cases 
that synthesis was not supported by an established method, but 
rather left to the professional judgment of a single individual.
As a starting point, the working group established a simple 
point-based framework that focused on a comprehensive cata-
loging of the relevant experimental and observational evidence, 
judging the strength of that evidence, and requiring that multiple 
pieces of evidence were present. We then applied that preliminary 
framework to the curation of a set of genes putatively involved 
in an array of hereditary cancers. While the framework was 
generally effective, we found that progress was slow, that much 
of the research we were doing had little long-term utility in the 
context of a diagnostic lab, and that there were regularly cases 
that led to a kind of logical conflict: genes supported by extensive 
and generally convincing research, where we were still unable to 
deliver positive results without additional clinical observations or 
experimental data.
We therefore re-convened the working group to reconsider 
the framework, with the following goals: (1) clearly define the 
purpose of the curation research effort, (2) identify the specific 
information that directly supported those aims, and (3) develop 
a reproducible and auditable approach to meet those aims. The 
group identified and discussed particular cases that led to disagree-
ments or inconsistency when using the previous approach, and 
worked through a series of thought experiments to elucidate edge 
cases. Through this process, the logical necessity of harmonizing 
variant evaluation and gene clinical validity evaluation emerged. 
As described below, the method that was developed simply defers 
the general question of the clinical validity of a gene to the specific 
question of the pathogenicity of clinically observed variants.
With this framework in place, we then applied the method 
to the set of genes suggested to cause hereditary cardiac con-
ditions. For each considered gene, we used the Human Gene 
Mutation Database (HGMD) to provide a list of published, 
clinically observed variants. The presence of a variant in the 
HGMD database does not necessarily indicate pathogenicity, and 
variants were independently researched and interpreted using an 
implementation of the ACMG variant interpretation guidelines. 
In the case where none of the variants listed in HGMD were 
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determined to be convincingly pathogenic, a literature search 
for more recent case reports of other clinically observed variants 
was performed.
resUlTs
establishing the clinical Validity  
of gene–condition relationships
Method for Establishing the Clinical Validity of a 
Particular Gene
The approach described here addresses the question of distin-
guishing between genes that have been proven to cause human 
disease and genes that currently only have preliminary evidence 
suggesting an association. It depends on a simple insight: an 
accurate methodology for evaluating variant pathogenicity must 
provide results that are consistent with an accurate methodology 
for evaluating the clinical validity of the gene. If the methodolo-
gies provide inconsistent results, one of the methodologies must 
be delivering an incorrect conclusion. This dependency suggests 
that the approaches can and should be harmonized.
This dependency can be demonstrated with a logical argument:
•	 Clinical validity of a gene is established when we know that the 
gene causes human disease.
•	 A gene causes human disease because at least one variant in 
the gene causes human disease.
•	 Therefore, clinical validity of a gene is established when we 
know of at least one variant in the gene that causes human 
disease.
•	 If the variant classification schema is robust, we know that a 
variant causes disease only when there is sufficient evidence to 
classify the variant as pathogenic.
•	 Therefore:
⚬ If there is sufficient evidence to classify a variant as patho-
genic, then we know that the variant causes disease, we know 
that the gene causes disease, and we know that a clinical test 
of the gene can be clinically valid.
•	 Conversely:
⚬ If there is NOT sufficient evidence to classify any clinically 
observed variants as pathogenic (i.e., if ALL clinically 
observed variants must be classified as VUS), then we do 
not know of a variant in the gene that has been proven to 
cause disease in humans, we can not be certain that the gene 
causes disease, and we do not know that a test of the gene 
would be clinically valid.
This argument reduces the question of evaluating the strength 
of the evidence supporting a causal gene–condition relationship to 
the more tractable question of the formal classification of clini-
cally observed variants.
This approach depends on a robust and rigorous variant 
classification method, such as a careful implementation of 
the American College of Medical Genetics (ACMG) variant 
classification guidelines. These guidelines classify observations 
about the consequence and context of a variant into one of a 
series of “evidence types.” Each evidence type contributes a 
predetermined amount to the argument that a variant is benign 
or pathogenic, and thresholds are suggested for the amount of 
evidence required to reach a certain classification. Admissible 
evidence may include family segregation data, observations in 
multiple, unrelated, clinically affected individuals, absence in 
healthy controls, animal models demonstrating recapitulation of 
a human disease phenotype, and functional data demonstrating 
an aberrant effect on the protein or transcript. The conclusion 
that a variant is pathogenic generally requires more than one type 
of strong evidence consistent with pathogenicity, and generally 
requires the observation of the variant in multiple, unrelated, 
similarly affected individuals.
The number of different pathogenic variants a gene harbors 
is not relevant to the general question of clinical validity. In fact 
there are many cases, especially in genes with gain-of-function 
disease mechanism, where all known incidences of the disease 
are caused by the same, specific pathogenic variant. In these 
cases, the clinical validity of the gene test is still established by 
the determination that that single variant is pathogenic.
One possible objection is that the assessment of a variant’s 
pathogenicity depends on already knowing the strength of the 
gene–condition relationship. We would argue that a careful 
application of the variant classification framework already takes 
the relevant uncertainties into account. The ACMG framework 
provides a series of cautions about using information of tan-
gential relevance: for example, case reports from individuals 
with possibly unrelated presentations, or assumptions about 
molecular mechanism. The power of case reports should be 
modulated based on the relevance and specificity of the pre-
senting phenotype. Before the gene has been well established 
as a cause of disease, any case report should be treated with 
this caution. The significance of the effect of the change on the 
RNA or protein should be modulated based on the understand-
ing of the molecular mechanism of disease. Before the gene 
has been well established as a cause of disease, all sequence 
observations should be treated with this caution. If these cautions 
are respected, it will be impossible to conclude that a variant 
is pathogenic without substantial evidence of multiple types 
supporting the conclusion.
If there is a clinically observed variant that can be classified as 
pathogenic, then it has been proven that the gene causes human 
disease.
Gene–Condition Strength Terminology
We describe the strength of the evidence supporting a possible 
relationship between a gene and a particular condition as either 
“strong,” “suggested,” or “emerging.”
•	 “Strong” is used in cases where there exists at least one clin-
ically observed variant supported by sufficient evidence to 
classify that variant as pathogenic. “Strong” indicates that the 
relationship has been proven.
•	 “Suggested” is used in cases where some preliminary evidence 
exists suggesting a causal relationship, but the relationship has 
not yet been formally proven.
•	 “Emerging” is used to describe a growing suspicion that a 
specific condition is caused by a gene that has already been 
proven to cause disease.
4Garcia et al. Framework for Clinical Validity
Frontiers in Cardiovascular Medicine | www.frontiersin.org June 2016 | Volume 3 | Article 20
If a gene has at least one “strong” relationship, then clinical 
validity for that gene has been established. If a gene has no “strong” 
relationships, then clinical validity has not been established, and 
the gene remains a “Gene of Uncertain Significance.”
Establishing Specificity in the Associated Clinical 
Phenotype
It is important to be as specific as possible with regard to the 
condition(s) associated with a gene. However in some cases we 
recognize that, while it is clear that the gene causes disease, there 
are too few case reports to derive any confidence about which 
disease, or if that disease matches neatly with any known and 
established clinical entities.
We address this question by a two-step process. We first 
establish that the gene causes disease by considering its relation-
ship to a generic entity referred to as “GENE-related conditions.” 
We then consider if that generic entity can be refined into one or 
more specific conditions.
Our approach to this question relies on a heuristic. In order to 
consider the relationship between a gene and a specific condition 
as “strong,” we require the observation of a pathogenic variant 
in three unrelated individuals who manifest the specific condi-
tion. If only one or two case reports describing individuals with 
pathogenic variants and manifesting a specific condition are 
available, we consider the specific gene–condition relationship to 
be “emerging.” The decision to require three individuals is not 
a statistical assessment, but is meant as a simple hedge against 
coincidences of individual expressivity or complex individual 
genotype; a non-classical clinical presentation in an affected 
individual may simply reflect an expansion of disease presenta-
tion or a modification of the presentation due to other genetic or 
external modifiers.
A gene can be well established as the cause of one specific 
condition, and also purported to cause an additional condition. In 
some cases, the conditions are distinct enough to be thought of as 
separate entities, and in some cases, the second condition should 
be thought of as a phenotypic expansion of the gene-specific, clini-
cal manifestation. This distinction can be somewhat subjective. In 
general, if individuals with pathogenic variants and both pheno-
types are reported, we consider this to be evidence in support of 
the idea that the phenotype associated with that gene is complex, 
rather than the idea that the gene causes two distinct conditions.
This is of special importance in cardiac genetics where some 
distinct conditions exist, where common mechanisms may cause 
one clinical condition to progress to presenting features of a second, 
and where there is extensive clinical overlap between some closely 
related conditions. Furthermore, because some cardiac conditions 
display reduced penetrance and/or later onset, the simple fact 
of observing a pathogenic variant in a single individual with an 
unexpected phenotype is not sufficient to establish a relationship 
between this variant and the carrier’s condition.
evaluation of cardiac genes: examples 
and summary
For each gene purported to be associated with a cardiac condi-
tion, we evaluated the evidence supporting the pathogenicity of 
the published, clinically observed variants. The full conclusions 
of our assessments of the genes associated with arrhythmias, 
cardiomyopathies, and the related syndromes are presented in 
Tables 1 and 2, and detailed examples of Strong, Suggested, and 
Emerging relationships are described below.
Establishing a Single Condition as “Strong”
The MYH7 gene has long been understood to be a cause of 
Hypertrophic Cardiomyopathy (HCM), a relationship which is 
clearly illustrated by the well-known, pathogenic p.Arg403Gln 
variant. This variant is absent from control populations, but has 
been shown to strongly segregate with HCM in four families 
with an overall LOD score of 3.4 (4–7). In addition, experimental 
studies have demonstrated that this change leads to defective 
ATPase activity and significantly alters actin motility (8–13). 
Furthermore, this variant has been shown to cause HCM in 
both transgenic mouse and rabbit models (14, 15). The clinical, 
functional, population, and animal data clearly establish this 
variant as pathogenic, and an abundance of individuals with this 
variant and a classic HCM phenotype have been reported. This 
pathogenic variant in MYH7 causes HCM, and the link between 
MYH7 and HCM is therefore established.
Multiple “Strong” Conditions Caused  
by the Same Gene
KCNQ1, the potassium voltage-gated channel, is an example 
of a gene that causes two clinically distinct conditions: Jervell 
and Lange-Nielsen Syndrome (JNLS), and long QT syndrome 
(LQTS).
Jervell and Lange-Nielsen Syndrome is an autosomal reces-
sive, multisystem disorder characterized by congenital profound 
bilateral sensorineural hearing loss and prolonged QT interval 
at a young age. Onset of cardiac symptoms typically occurs in 
childhood, and arrhythmia due to JLNS may result in recurrent 
syncope, seizure-like activity, or sudden cardiac arrest/death. In 
addition to congenital hearing loss and cardiac symptoms, some 
individuals with JLNS have also been found to have anemia and 
elevated levels of the hormone gastrin.
Although a range of variants can be pathogenic, a common 
pathogenic JLNS variant is p.Arg518*, a founder mutation in the 
Swedish population. It has been observed in the homozygous state 
in a number of JLNS patients, and as a compound heterozygote 
with other truncating variants (16–18).
In addition, heterozygous carriers of pathogenic variants are 
affected by LQTS of varying severity. LQTS is characterized by 
a prolonged QTc interval on electrocardiogram (ECG/EKG) and 
cardiac arrhythmia, such as torsade de pointes, that may result 
in recurrent syncope, seizure-like activity, and sudden cardiac 
arrest/death (19, 20). Although mild hearing loss can sometimes 
be an associated symptom of LQTS, it is a recognizably distinct 
clinical entity from JLNS. In one study, 12 heterozygous carriers 
of the pathogenic p.Arg518* variant were demonstrated to have 
prolonged QT segments and normal hearing (18).
This series of case studies of individuals with variants that 
are known to be pathogenic, and who are affected by LQTS 
and not JLNS, establishes the relationship between KCNQ1 
and LQTS.
TaBle 1 | gene–condition strengths for selected cardiomyopathies.
hcM DcM arVD/c lVnc Overlapping cardiomyopathy syndromes
MYBPC3 Strong Strong Suggested
MYH7 Strong Strong Strong Strong: Laing distal myopathy 
PLN Strong Strong Strong Emerging
TNNC1 Strong Strong
TNNT2 Strong Strong Strong
TPM1 Strong Strong Suggested
TNNI3 Strong Strong Suggested
TTN Strong Strong: titinopathies 
LMNA Strong Suggested Suggested Strong: laminopathies 
DSP Strong Strong Strong: Carvajal syndrome 
RBM20 Strong Suggested
VCL Emerging Strong
TAZ Strong Strong Strong: Barth syndrome 
DSG2 Strong Strong  
DES Strong Strong Strong: desminopathy 
BAG3 Strong Strong: myofibrillar myopathy 
SCN5A Strong Strong Suggested  
DMD Strong Strong: Duchenne muscular dystrophy 
RAF1 Strong  
ACTC1 Strong Emerging Strong  
ACTN2 Strong Emerging Emerging  
CSRP3 Strong Suggested  
FHL1 Strong Strong: Emery–Dreifuss muscular dystrophy 
GLA Strong: Fabry disease 
MYL2 Strong  
MYL3 Strong  
PRKAG2 Strong Strong: glycogen storage disease 
HCN4 Strong  
RYR2 Emerging Strong Strong  
LAMP2 Emerging Strong: Danon disease 
TTR Strong: transthyretin amyloidosis 
ELAC2 Strong: combined oxidative phosphorylation deficiency 
MTO1 Strong: combined oxidative phosphorylation deficiency 
CAV3 Suggested Strong: caveolinopathies 
ALMS1 Strong: Alstrom syndrome 
EMD Emerging Strong: Emery–Dreifuss muscular dystrophy 
FKRP Strong: muscular dystrophy 
FKTN Strong: muscular dystrophy 
JUP Suggested Strong Strong: Naxos disease 
SDHA Strong: mitochondrial complex II deficiency 
TMEM43 Strong Suggested: Emery–Dreifuss muscular dystrophy 
DSC2 Suggested Strong Strong: RVC with palmoplantar keratoderma and  
wooly hair 
PKP2 Suggested Strong  
TCAP Suggested Suggested Strong: limb girdle muscular dystrophy 
ABCC9 Suggested Strong: Cantu syndrome 
SGCD Suggested Strong: limb girdle muscular dystrophy 
This table presents assessments of the strength of each gene–condition associations across the cardiomyopathies. Specific references for each cell in this table are available in the 
Supplementary Material.
The following genes have only “suggested” relationships to cardiac conditions, and are therefore classified as preliminary evidence genes: LDB3, ANKRD1, PDLIM3, MYPN, NEXN, 
CALR3, JPH2, MYLK2, MYOM1, MYOZ2, PRDM16, CRYAB, CTF1, FHL2, GATA6, GATAD1, ILK, LAMA4, NEBL, NPPA, TMPO, TXNRD2, DTNA, CTNNA3.
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TaBle 2 | gene–condition strengths for selected arrhythmias.
long QT 
syndrome
short QT 
syndrome
Brugada 
syndrome
cPVT Overlapping 
arrhythmia 
syndrome
KCNH2 Strong Strong Suggested
KCNQ1 Strong Emerging Strong: Jervell 
Lange-Nielsen 
syndrome
SCN5A Strong Strong
CASQ2 Strong
RYR2 Strong
CAV3 Strong
KCNE1 Strong Strong: Jervell 
Lange-Nielsen 
syndrome
KCNE2 Strong
CALM1 Strong Strong
CALM2 Strong Strong
CALM3 Strong Strong
TRDN Strong Strong
KCNJ2 Emerging Strong Emerging Strong: 
Anderson-Tawil
CACNB2 Strong Strong
GPD1L Strong
CACNA1C Strong Suggested Suggested Strong: 
Timothy 
syndrome
This table presents assessments of the strength of each gene–condition associations 
across the arrhythmias. Specific references for each cell in this table are available in the 
supplemental materials.
The following genes have only “suggested” relationships to cardiac conditions, and are 
therefore classified as preliminary evidence genes: SCN4B, SNTA1, TRPM4, KCNE3, 
KCNE5, RANGRF, SLMAP, KCNJ8, SCN3B, SCN2B, and SCN10A.
CPVT, catecholaminergic polymorphic ventricular tachycardia.
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“Strong” First Condition and “Emerging” Second 
Condition
In addition to LQTS and JLNS, there is some emerging evi-
dence that certain variants in KCNQ1 also cause Short QT 
Syndrome (SQTS). Short QT syndrome is characterized by 
a shortened QTc interval on electrocardiogram and cardiac 
arrhythmias that may result in syncope, seizure-like activity, 
and/or sudden cardiac arrest/death (21, 22). To date, there 
are two relevant case reports: (1) a 70-year-old male has been 
observed with SQT and a p.Val307Leu variant. While there 
is functional evidence that p.Val307Leu could contribute to 
a gain-of-function phenotype (23), this variant would still be 
formally classified as a VUS until additional case reports or 
segregation data became available. (2)  An infant with severe 
fetal bradycardia, irregular rhythm, and short QT who has a 
de novo p.Val141Met variant. In this case also, there is some 
functional evidence that this mutation has a gain-of-function 
effect (24). The de novo observation contributes strongly to 
this variant’s pathogenic classification.
At this time, there is one report of an individual with a patho-
genic variant in KCNQ1 and a severe short QT/arrhythmogenic 
phenotype. It is quite likely that certain gain-of-function muta-
tions in KCNQ1 cause short QT; however, it is also possible that 
these variants are coincidental observations in individuals whose 
true causative variant remains undiscovered. Until additional 
case reports come to light, we classify the relationship between 
KCNQ1 and short QT syndrome as “emerging.”
Single Condition Example: “Suggested”
SCN10A may be a gene that causes Brugada syndrome, although 
this has not yet been proven. While SCN5A is the primary cause 
of Brugada syndrome, rare SCN10A variants have been found in 
about 16% of SCN5A-negative Brugada patients. All told, there 
have been around 30 missense changes observed in Brugada 
patients (25, 26); however, a detailed evaluation of the underlying 
evidence regarding each of these variants leads us to conclude 
that every one of these variants should be classified as VUS. 
Most of these variants are supported by little evidence beyond 
an observation in an individual, absence in the general popu-
lation, and computational predictors. There are two reported 
variants that have been explored more thoroughly, p.Arg14Leu 
and p.Arg1268Gln. These variants have each been observed in 
four individuals with Brugada signs, and experimental evidence 
seems to demonstrate that in an in  vitro co-expression model, 
introducing these variants into SCN10A leads to a significant 
reduction in SCN5A current (26). However, these variants are 
also relatively common in the general population, with hundreds 
of observations in ExAC. Taken together, and in the absence 
of compelling segregation data, even these two variants must 
remain classified as VUSes.
At this point, there exist no clinically observed variants in 
SCN10A that can be classified as pathogenic, and therefore we 
cannot be certain that pathogenic variants in SCN10A cause 
Brugada syndrome. For this reason, we classify the relationship 
between SCN10A and Brugada as “suggested.”
Syndromic Genes and Isolated Phenotypes
Pathogenic variants in genes that are primarily associated with 
syndromes can sometimes manifest clinically as isolated cardiac 
conditions. This can be because other symptoms have not yet 
developed, because other symptoms are subtly present and have 
escaped notice, or because the gene truly also causes the isolated 
phenotype. How should we think about the range of conditions 
caused by mutations in these genes?
For example, do some pathogenic variants in DMD cause 
isolated dilated cardiomyopathy (DCM)? The evidence that they 
may includes: (1) in one large family, isolated DCM in the absence 
of Duchenne or Becker muscular dystrophy mapped to the DMD 
gene (27), (2) a collection of case studies identified classically 
pathogenic DMD variants (exonic deletions or splice variants) in 
individuals with DCM and without additional features associated 
with muscular dystrophy (28–30), (3) a study which evaluated 
the DMD gene (called DYS in this paper) in a series of 436 male 
patients diagnosed with isolated DCM, the authors identified 
pathogenic deletions or splice variants in 34 patients (31). Upon 
closer inspection, many of these individuals with “isolated” DCM 
had elevated serum creatine phosphokinase and/or mild skeletal 
myopathy. However, there were six individuals with classically 
pathogenic DMD variants who did not have any signs of latent or 
undiagnosed muscular dystrophy.
7Garcia et al. Framework for Clinical Validity
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There are, therefore, a collection of individuals with isolated 
DCM whose phenotypes can clearly be explained by identified, 
pathogenic variants in DMD. We would argue that this series of 
patients establishes the relationship between DMD and isolated 
DCM. We would also suggest, however, that this is largely a 
semantic distinction. One can say, “Pathogenic variants in 
DMD can, in some cases, lead to isolated DCM” or one can say 
“Pathogenic variants in DMD cause Becker syndrome, which in 
some cases can present as (and not progress beyond) isolated 
DCM” and these amount to much the same thing in practice. 
A patient who has what is apparently isolated DCM should be 
evaluated for potential pathogenic variants in the DMD gene, 
as such a variant may be the cause of this patient’s condition. 
Likewise, a patient with a pathogenic variant in DMD should be 
carefully examined and monitored for other symptoms of Becker 
muscular dystrophy as additional symptoms may be subtle or 
may appear with a later onset.
FHL1 presents another example of this logic. FHL1 is a 
well established, “strong” cause of Emery Dreifuss muscular 
dystrophy (EDMD) and may also cause isolated HCM. Some 
EDMD patients develop HCM (32), and there are many reports 
of patients with pathogenic variants in FHL1 who present with 
isolated HCM and who have no other symptoms of EDMD. These 
include: (1) a small pedigree of three individuals with isolated 
HCM that segregates with an FHL1 truncation variant, (2) an 
unrelated individual with isolated HCM and an apparently de 
novo frameshift variant (33), and (3) a three generation pedigree 
manifesting HCM that segregates with different truncating FHL1 
variants (34). This series of individuals with pathogenic variants 
in FHL1, with a clinical diagnosis of HCM but with no evidence 
of EDMD, establishes the relationship between FHL1 and isolated 
HCM. However, there is no clear genotype/phenotype correla-
tion distinguishing variants that cause EDMD from variants that 
cause isolated HCM, and the differing manifestations may be 
due to other genetic or environmental factors specific to these 
individuals or families. Patients with isolated HCM should be 
evaluated for variants in the FHL1 gene, and patients with patho-
genic FHL1 variants should be carefully examined for features 
of EDMD.
Panel Design and clinical Overlap among 
cardiac conditions
Conventional cardiac evaluations may not accurately determine 
an individual’s true, underlying diagnosis. For example, left 
ventricular hypertrophy observed on an echocardiographic 
evaluation is typically associated with isolated HCM but may 
also be the primary presenting feature of an unrecognized 
syndromic condition such as Noonan syndrome or Fabry dis-
ease (35). “End-stage” HCM is characterized by left ventricular 
dilation, and isolated echocardiogram results can easily lead to 
a misdiagnosis of primary DCM (36). Ventricular arrhythmia, 
conduction disease, cardiac arrest or unexplained syncope, in the 
absence of secondary causes, could either represent a primary 
inherited arrhythmia syndrome or the early clinical presentation 
of an arrhythmogenic cardiomyopathy (37–41). Clinicians and 
professional organizations have recognized the importance of 
comprehensive genetic testing to aid in the diagnosis of cardiac 
conditions (42), and panel design should address these issues of 
overlapping and misleading clinical presentation.
We propose that a comprehensive panel test designed for the 
molecular diagnosis of a particular condition should include the 
following classes of genes:
•	 Genes that have been conclusively proven to cause the condi-
tion in question.
•	 Genes suspected but not yet proven to cause the condition in 
question.
•	 Genes that have been conclusively proven to cause a condition 
within the clinical differential. This category should include 
genes that cause a condition that can progress into the con-
dition in question, genes that cause a condition that can be 
confused with the condition in question, and genes that cause 
a syndrome that include the condition in question as a primary 
feature.
We suggest that the clinical validity of a panel is established 
when that panel includes a set of genes that account for a substan-
tial proportion of the genetic causes of the disease in question. 
Conversely, a panel is NOT valid if it omits certain genes that 
account for a substantial proportion of the known genetic risk. 
A clinically valid panel may also include genes for which some 
preliminary evidence of clinical validity exists (“preliminary 
evidence genes”).
A panel test for HCM should include, therefore, genes proven 
or suspected to cause isolated HCM, and genes proven to cause 
conditions that can present with HCM as a primary feature, such 
as Fabry disease.
Likewise, a panel for DCM should include genes proven or 
suspected to cause isolated DCM, genes proven to cause HCM 
(because HCM can progress to, and be observed as, DCM), and 
genes proven to cause arrhythmogenic right ventricular dyspla-
sia or cardiomyopathy (ARVD/C, because ARVD/C can present 
as DCM).
A selected mapping of clinically presenting features to their 
potential underlying clinical conditions is presented in Table 3. 
While this mapping is not meant to be comprehensive, it is 
intended to illustrate some of the common discrepancies and 
overlaps.
DiscUssiOn
The three pillars of effective diagnostic medicine are analytic 
validity, clinical validity, and clinical utility. Establishing the 
clinical validity of a multi-gene panel depends on an accurate 
and detailed understanding of the strength of the evidence 
that establishes a causal relationship between the included 
genes and human disease. We have established methods to 
establish gene-level clinical validity, to construct meaningful 
panel tests, and have applied these methods to a set of cardiac 
gene–condition pairs.
Before the advent of exome sequencing, gene–conditions 
associations were traditionally established through the use 
of gene-mapping techniques. This approach required the 
ascertainment of multiple, large affected families to provide 
TaBle 3 | clinical overlap of selected inherited arrhythmias and cardiomyopathies.
…may actually represent a true case of:
hcM DcM arVD/c long QT short QT Brugada cPVT Unspecified 
arrhythmia
noonan 
syndrome/
rasopathy
Fabry 
diseasea
DMD/
Beckera
A
 c
lin
ic
al
  
pr
es
en
ta
tio
n 
of
…
HCM ✓ ✓ ✓
DCM ✓ ✓ ✓ ✓
Unspecified 
cardiomyopathy
✓ ✓ ✓ ✓ ✓ ✓
ARVD/C ✓ ✓ ✓ ✓ ✓
Unspecified 
arrhythmia
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Specific cardiac presentations can reflect a wide range of underlying conditions. Understanding the spectrum of conditions that can present with particular features is an important 
first consideration in the planning of diagnostic panels. This table presents some of these relationships.
aNoonan, Fabry and DMD/Becker are included as representative examples only. Other overlapping syndromic conditions exist but are not represented in this table [adapted from  
Pagon et al. (44)].
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sufficient power to establish linkage to relatively small genomic 
regions. Genes within the identified regions were then analyzed 
further for possibly causal variants, or for functional or bio-
logical relevance. This was an effective strategy when the cost 
of expansively sequencing an individual was prohibitive, but 
was limited in that it relied on the availability of large pedigrees 
or multiple pedigrees that shared the same underlying genetic 
cause. Sufficient families are generally only available in the cases 
where a single gene explains a substantial number of cases of a 
particular condition.
As the cost of sequencing has come down, it has become 
feasible to bypass the process of narrowing the genomic search 
space, and to move directly to the search for causal variants. 
This has allowed the clinical research community to take greater 
advantage of isolated unrelated individuals and small pedigrees 
to generate meaningful genetic hypotheses. The increased 
accessibility of exome sequencing, for example, has led to an 
explosion of hypotheses about gene–condition relationships. The 
consequence is that we have a greater appreciation of the specific 
genetic diversity underlying many conditions, but also that the 
amount of data available to support a particular hypothesis is 
often substantially limited. As diagnostic testing moves to include 
these genes in routinely available tests, there is a need for an 
efficient and reproducible method for evaluating the strength of 
the evidence suggesting a causal relationship. Meaningful panel 
design, and the appropriate understanding and use of results 
derived from the included genes, depend on this fundamental 
understanding.
clinical Validity of a Panel Test
This paper aims to provide a method for establishing clinical 
validity of individual genes that is consistent with the general 
ACCE framework. We also note that, although clinical practice is 
quickly moving to embrace panel testing, a clear framework does 
not exist for establishing clinical validity on a panel level. Some 
entities suggest that clinical validity of a panel is established when 
each and every included gene has established validity; however, 
this assertion is refuted by the rapid adoption of exome testing as 
a viable, clinically valid option.
For many conditions, the bulk of the diagnostic yield of a panel 
test is accounted for by pathogenic variants in a small number of 
genes, and is supplemented by a “long tail” of genes that account 
for rare cases. In addition, there can be real benefit to patients to 
testing genes in advance of their clinical validity being conclu-
sively established.
We therefore propose that the clinical validity of the panel test 
is largely established by the inclusion of genes that account for the 
bulk of the diagnostic yield for that condition. Conversely, a panel 
test should be considered to be out-of-date and no longer clini-
cally valid if it fails to include such genes. For example, a clinically 
valid test for HCM must include MYBPC3, as pathogenic variants 
in this gene account for a substantial portion of HCM cases, 
and an HCM panel that fails to include this gene should not be. 
However, a panel should not be bounded by the current state of 
information, for the reasons described below. An effective HCM 
panel may also include a series of preliminary evidence genes that 
may turn out to contribute additional clinical sensitivity, but that 
cannot do so at this point in time.
Utility of Findings in the Three classes of 
genes
Broadly speaking, genes are included in a panel for one of the three 
reasons listed below. The utility of findings in the gene depends 
on the categorization of the gene and the reason for inclusion.
Genes That Definitively Cause a Condition within the 
Patient’s Differential
When pathogenic variants are identified in these genes, these 
variants likely represent a causal explanation for the individual’s 
condition. Pathogenic variants in these genes can inform the 
prognosis, management, and treatment of the affected individual. 
Pathogenic variants are also material to the health and clinical 
management of the proband’s family members. Asymptomatic 
relatives who carry the variant may be candidates for more 
aggressive screening, monitoring, or prophylactic interventions. 
Asymptomatic relatives who do not carry the pathogenic familial 
variants may be returned to standard monitoring protocols for 
their demographic.
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When variants of uncertain significance (VUSes) are identi-
fied in these genes, testing of similarly affected family members 
may be useful in understanding the clinical significance of the 
variant. Segregation of the variant with disease can inform the 
relevance of the variant to the particular family, and may inform 
the formal classification of the variant.
Most of the diagnostic yield from a panel test is derived from 
these genes, and testing broadly beyond this class of genes does 
not substantially increase that yield (35).
Genes That Definitively Cause a Related or Similar 
Condition, but That Have Not Been Definitively 
Proven to Cause the Proband’s Condition
The clinical overlap between many cardiac conditions is exten-
sive. Furthermore, we know that our understanding of the full 
phenotypic heterogeneity of many of these genes may be limited. 
It will come as no surprise when evidence emerges demonstrat-
ing that pathogenic variants in any one gene can lead to a larger 
range of phenotypes than we currently appreciate. Because of this, 
more clinicians are opting to test genes that have been definitively 
proven to cause a related disease in their diagnostic testing regi-
mens. However, the utility of findings in such genes is different 
than that described above.
When pathogenic variants are identified in these genes, they 
can mean one of a few things. The variant may represent the true 
cause of the patient’s condition, and may indicate that the patient 
represents an expansion of the clinical phenotype previously 
associated with the gene. However, due to the prevalence of some 
cardiac conditions, families affected by more than one condition 
are not uncommon. The pathogenic variant may, therefore, be an 
incidental finding, and may indicate that the individual is also at 
risk for a second condition. The pathogenic finding is still relevant 
to asymptomatic family members; however, caution should be 
applied as the observation in the first proband may suggest that 
the variant is incompletely penetrant in this family. Discovery of 
pathogenic or uncertain variants in these genes in a patient should 
stimulate a thorough review of the clinical presentation through the 
lens of the new hypothesis. The patient may have subtle features of 
the associated clinical condition that were not initially appreciated.
When a VUS is identified in one of these genes, segregation 
data can be difficult to parse. Segregation analysis depends on the 
co-occurrence of the variant with an associated condition. But if 
it is not yet certain that the gene causes the condition, individuals 
with that condition are not necessarily informative. If the variant 
does not segregate with the condition in the family, then it is 
certainly not likely to be the cause of disease. In this situation, 
clinicians and patients must wait for additional information to 
emerge regarding the spectrum of clinical presentations associ-
ated with clearly pathogenic variants in the gene.
Genes That Have Not yet Been Proven to Cause Any 
Condition: Only “Suggested” Gene–Condition 
Relationships
Genetic testing panels routinely include “candidate” or “pre-
liminary evidence” genes (genes with no more than “suggested” 
relationships to any clinical condition), and for good reason. The 
cost of generating and holding additional patient data has become 
marginal, we expect our understanding of genetics to improve 
rapidly over the next years, and an appropriate use of this infor-
mation does not increase downstream clinical cost or burden.
It is, by definition, not possible to identify pathogenic variants 
in genes which have not been proven to cause any condition. 
Variants that are identified in these genes are not used to guide 
monitoring or treatment decisions. They are also not used to 
inform risk in family members. However, variants identified in 
these genes are held in the patient record or by the lab so that, 
if and when new information becomes available, that informa-
tion can become useful to the patient without having to endure 
the cost and time of a second genetic test. Additionally, testing 
these genes can help identify patients and families who may be 
referred to research studies to help support an expansion of our 
understanding of the condition and the genetics.
Other necessary information for the 
accurate interpretation of Variants
This paper focuses on establishing the clinical validity of par-
ticular genes. It should be clear, however, that although clinical 
validity is a primary consideration, it does not encapsulate all of 
the relevant details one would need to accurately interpret novel 
sequence variants. Such details include molecular mechanism of 
disease, inheritance patterns associated with disease, penetrance, 
age-of-onset, severity of disease, the consequence of homozygous 
variants, relevant protein domains, the frequency of de novo 
variants, etc. The framework for rigorously establishing these 
qualities is beyond the scope of this paper. If it has been proven 
that the gene causes disease, then questions of “how?” and “by 
what mechanism?” become relevant.
Other gene–condition classification 
efforts
Besides the approach outlined in this paper, there exist other, prom-
ising efforts to tackle this essential question of the evaluation of the 
strength of the purported gene–condition relationship. Among the 
most promising is being developed by the ClinGen Gene Curation 
Working Group, a part of the broader ClinGen effort (43). This 
working group is developing a framework for evaluating the 
strength of the evidence that supports a gene–condition relation-
ship that is similarly based on the structured evaluation of underly-
ing evidence. We expect that group’s efforts to ultimately become 
the authoritative source for this sort of information. However in 
order for that to happen, that approach must be finalized and then 
broadly accepted and adopted with the support of the larger clinical 
genomics community. Equally importantly, it must be supported 
and maintained by an extensive community-based curation effort 
that will march through the Mendeliome and the array of possibly 
associated conditions. For labs and clinicians working in clinical 
genetics now, it is simply not possible to defer patient care until 
these community-based resources can mature.
cOnclUsiOn
The design of effective diagnostic tests, the clinical validity of 
those tests, and the effective use of the results of such tests, 
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depends on a clear understanding of the relationship between 
each gene and each considered condition. This paper clearly 
describes a general methodology establishing clinical validity 
of a gene that can easily be applied across clinical areas. For an 
active clinical lab, the benefits of the variant-centric approach 
to the question of clinical validity should be evident: it allows 
the lab to maintain one consistent lens for assessing clinical 
molecular genetics, capitalizes on the variant classification 
method and the infrastructure to support that method, and 
reduces logical inconsistencies that arise from using different 
schema to evaluate the relationship between genetic changes 
and human disease.
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